Summary
The provided statements address manufacturers/ownership/handling and do not make any drug-label claims about DALVANCE’s indication, dosing, contraindications, warnings, interactions, or safety. These statements cannot be verified against the supplied prescribing information and therefore cannot be confirmed as on-label.
Category Scores
Accurate Statements
Unsupported Statements
Dalbavancin (brand name Dalvance) is manufactured and marketed by Durata Therapeutics and its partners.
Not supported by the supplied prescribing information sections (no manufacturer/marketing/ownership details provided).
After Durata’s acquisition-related transactions, dalbavancin has been handled through companies associated with Allergan/AbbVie’s portfolio.
Not supported by the supplied prescribing information sections (no post-acquisition handling/portfolio ownership details provided).
After Durata’s acquisition-related transactions, dalbavancin has been handled through Durata’s legacy commercial rights, depending on the market and timeframe.
Not supported by the supplied prescribing information sections (no legacy commercial rights/market-by-market handling details provided).
Contradictions
Important Omissions
No AI-generated content provided regarding DALVANCE’s on-label indication (ABSSSI due to designated susceptible Gram-positive organisms), dosing/regimens and infusion instructions, contraindications, warnings/precautions, adverse reactions, or any required monitoring/administration/storage details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The statements are about manufacturing/handling ownership rather than prescribing, dosing, contraindications, or safety. However, because they cannot be verified from the supplied label excerpts, their accuracy relative to FDA-approved labeling is indeterminate.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Applicable
Primary Issue
No label-relevant prescribing information was provided in the AI statements; manufacturing/ownership claims are not present in the supplied prescribing information and cannot be verified.
Suggested Improvement
Provide the actual AI-generated prescribing/clinical content to be audited against the label (e.g., indication, dosage regimen and infusion time, contraindications, warnings/precautions, adverse reactions, or administration/storage). If discussing manufacturer/ownership, use sources beyond the prescribing information or cite where the label contains that information.